MRVT

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors.